Sinusoidal obstruction syndrome (SOS) is a potentially fatal complication of hematopoietic stem cell transplantation (HSCT). Traditional ultrasound (US) has poor sensitivity and specificity. US shear wave elastography (SWE) is a newer technology that measures liver stiffness. This is a single-institution, prospective cohort study evaluating SWE in patients younger than 21 years who received HSCT from December 2015 through June 2017. SOS was defined using the modified Seattle criteria. Subjects had US with SWE at three scheduled time points. t-tests were used to assess for difference between the groups and ROC curves were generated. Twenty-five patients were included. Five subjects developed SOS. At day +5 HSCT, SOS patients had SWE velocities that increased by 0.25 ± 0.21 m/s compared to 0.02 ± 0.18 in patients without SOS (p = 0.020). At day +14, SOS patients had SWE velocities that significantly increased by 0.91 m/s ± 1.14 m/s compared to 0.03 m/s ± 0.23 m/s in patients without SOS (p = 0.010). SWE SOS diagnosis occurred on average 9 and 11 days before clinical and conventional US diagnosis, respectively. Patients who develop SOS have increased liver stiffness compared to patients who do not develop SOS. SWE changes occur before other imaging and clinical findings of SOS.
Introduction
Hepatic sinusoidal obstruction syndrome (SOS), previously termed hepatic veno-occlusive disease is a potentially fatal disease affecting children after hematopoietic stem cell transplantation (HSCT) with an overall incidence rate ranging from 5 to 60% [1] [2] [3] . HSCT is a standard therapeutic modality for a variety of malignant and non-malignant diseases. SOS is thought to be caused by chemotherapy damage to the sinusoidal endothelial cells. Damage to the endothelial cells results in activation of inflammatory and coagulation pathways causing clot formation and narrowing of sinusoids, ultimately resulting in hepatic venous congestion. The disease can be mild, moderate or severe. Children with severe SOS suffer from multi-organ failure with signs and symptoms of portal hypertension (ascites, varices, and/or edema) and renal and respiratory failure [4, 5] . Risk factors for developing SOS are age (younger patients are at greater risk), previous myeloablative HSCT, previous abdominal irradiation, hepatic fibrosis, and treatment with busulfan and gemtuzumab ozogamicin [1] . SOS is also one of the major causes of non-relapse, transplantrelated mortality with death rates reported as high as 84% in patients diagnosed with severe SOS [6] .
Hepatic SOS is characterized by conjugated hyperbilirubinemia, tender hepatomegaly and ascites and fluid accumulation manifested as rapid weight gain. Clinical diagnosis of SOS can be made by using the modified Seattle criteria [4] or Baltimore criteria [7] , both of which utilize clinical and laboratory parameters. The most accurate methods to diagnose SOS is liver biopsy [8] and measurement of the hepatic venous pressure gradient [9] through the jugular vein. However, these procedures are invasive, costly and require the expertise of specialized physicians to perform. Traditionally, conventional ultrasound (US) has routinely used to support the diagnosis of SOS, but has been shown to have poor sensitivity and specificity [10, 11] . Findings indicating SOS on conventional US are ascites, hepatic artery resistive index (RI) > 0.75 and hepatofugal portal venous blood flow.
Quantitative US shear wave elastography (SWE) with acoustic force radiation imaging (ARFI) is an emerging technology that uses US pressure waves to estimate tissue stiffness [12] [13] [14] . The SWE is proportional to the tissue elasticity: a stiffer liver will result in higher SWE measurements. Hepatic venous congestion should increase the stiffness of the liver. We therefore hypothesized that SWE would detect SOS earlier and more accurately than would conventional US imaging.
Materials and methods

Study design
The present study was performed in accordance with the ethical guidelines of the Helsinki Declaration and was approved by the local ethics committee. All study participants provided written informed consent. This is a single site prospective cohort study that evaluated limited abdominal US, Doppler and US SWE examinations in HSCT patients younger than 21 years from December 2015 through June 2017. Patients undergoing allogenic or autologous myeloablative stem cell transplant were included. Patients undergoing reduced intensity conditioning regimen were excluded. This trial was registered on ClinicalTrials.gov with identification number NCT02483481.
SWE image acquisition and analysis
All patients were enrolled into the study prior to their HSCT. After enrollment and within one week prior to starting their conditioning regimen, a limited abdominal US with Doppler measurements of the hepatic arteries, hepatic and portal veins, as well as US SWE was performed. The same study was repeated on day +5 and day +14 after HSCT. Additionally, when patients had clinical suspicion for SOS, the clinical team often ordered US exams as standard of care. SWE was added to all of these exams and these exams were included in our data analysis. All imaging was performed using GE Logiq E9 US machines by dedicated pediatric sonographers and interpreted by one pediatric radiologist on the study. At least ten shear wave velocities measurements were taken one-centimeter below the liver capsule at the mid-clavicular line avoiding areas of vasculature [12] . The sonographer performing the exam and the interpreting radiologist were not blinded to the clinical status of the patient. US data and clinical data were extracted from electronic medical records (Table 1) . Study data were collected and managed using REDCap electronic data capture tools hosted at The Children's Mercy Hosptial [15] . REDCap (Research Electronic Data Capture) is a secure, web-based application designed to support data capture for research studies, providing (1) an intuitive ll continuous values are presented as mean ± s.d. All categorical variables are presented as value (percentage). Bold values indicate significant differences between patients who developed SOS versus those who did not ALL acute lymphoblastic leukemia, AML acute myeloid leukemia, CML chronic myeloid leukemia * Calculated using student's t-test.^Calculated using chi-square or Fisher's exact test interface for validated data entry; (2) audit trails for tracking data manipulation and export procedures; (3) automated export procedures for seamless data downloads to common statistical packages; and (4) procedures for importing data from external sources.
Clinical variables
All of the clinical values were retrospectively extracted from the patients' electronic medical records by a single reviewer (ALR) and entered into REDCap. The diagnosis of SOS was based on the modified Seattle criteria which state at least two of the following criteria must be present within 20 days of HSCT: bilirubin ≥2 mg/dL; hepatomegaly and/or ascites; and/or weight gain ≥5% above baseline weight [4] . We used daily progress notes, lab values and weight measurements to determine if and when our included patients exceeded the criteria. We defined date of clinical diagnosis of SOS as the first date when the patient met the modified Seattle criteria. We defined the date of conventional imaging diagnosis of SOS as the first date on which Doppler US showed flow reversal in one of the right, left or main portal veins. We defined the date of SWE diagnosis of SOS as day +5 HSCT if the SWE increased greater than the day +5 HSCT value identified in our ROC analysis for day +5 HSCT. Otherwise, we defined it as the date on which the SWE increased greater than the day +14 HSCT value identified in our ROC analysis. This day could be any day after day +5 HSCT.
Statistical analysis
Per Society of Radiologists in US criteria, we used the median values from the US SWE. Descriptive statistics are reported as means ± standard deviation for continuous variables and frequency with percentage for categorical variables. Differences in SWE measurement outcomes between SOS and non-SOS groups were assessed using two-sided independent t-tests for continuous variables and Chi-square or Fisher's exact test for categorical variables, as appropriate based on sample size. Changes over time were compared using a linear trend test for continuous measurements and Mantel-Haenszel trend test for categorical variables. ROC curves were created to calculate area under the curve (AUC) for SWE change from pre-conditioning to day +5 HSCT and pre-conditioning to day + 14 HSCT. Optimal elastography cut-off point was determined using Youden's index.
All statistical tests were two-sided and conducted at the alpha = 0.05 level. Statistical analysis was done using The SAS software v 9.4 (Copyright, SAS Institute Inc. SAS and all other SAS Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc., 
Results
A total of 25 (17 allogenic and 8 autologous) subjects were included in our study. The median age of the patients was 9.1 years (range 2-21 years). Gender was equally distributed with 13 males (52.0%) and 12 females (48.0%). Twenty-four patients (96.0%) underwent HSCT for malignant disease, of which acute lymphoblastic leukemia (ALL) (n = 8, 33.3%) was the most common reason. One patient (4.0%) underwent HSCT for beta thalassemia major. The most common stem cell source was bone marrow in 11 (44.0%) patients, followed by peripheral blood in ten (40.0%) and umbilical cord in four (16.0%). The patients who developed SOS were younger, had a higher incidence of AML and were more likely to have received busulfan as a part of their conditioning regimen than patients that did not develop SOS (Table 1) . Eight (32.0%) patients in the study received busulfan as part of their conditioning regimen and four of which (50%) developed SOS. Five patients (20.0%) developed SOS ( Table 2 ). Four (80.0%) of the five SOS patients underwent allogenic and one (20.0%) underwent autologous HSCT. All five patients met the modified Seattle criteria and were diagnosed with SOS on days +14, +14, +18, +19 and +19 after HSCT.
Doppler US showed reversal of portal venous flow in four (80.0%) of the five patients who developed SOS (Fig. 1 ). There were no statistically significant differences in values on Doppler US between those that developed SOS versus those that did not for main hepatic artery (MHA) velocities, main hepatic artery RI and main portal vein velocity. US SWE showed increased velocities in all c d a b patients who developed SOS. SWE velocity values showed no differences between pre-conditioning median SWE velocities in the SOS group (1.24 ± 0.09 m/s) and non-SOS group (1.41 ± 0.18 m/s) (p = 0.060). By day +5, patients with SOS had SWE velocities that significantly increased by 0.25 ± 0.21 m/s from baseline compared to a 0.02 ± 0.18 m/s increase in patients without SOS from baseline (p = 0.020). By day +14, patients with SOS had SWE velocities that significantly increased by 0.91 ± 1.14 m/s from baseline compared to a 0.03 ± 0.23 m/s increase in patients without SOS from baseline (p = 0.010). These values are both clinically and statistically significant ( Table 3 and Fig. 2) , demonstrating that patients with SOS have significantly increased liver stiffness as measured by SWE compared to patients without SOS. Hepatofugal portal venous flow was noticed in 80% (n = 4) of SOS patients, occurring on days +15, +16, +19 and +21, respectively, after HSCT.
The SWE velocity values varied throughout the SOS patients' clinical courses. In general, the SWE velocities would peak at the same time that both the patient's SOS became clinically evident and reversal of portal venous flow occurred on Doppler US. The peak SWE velocity values also tended to occur around the date of the clinical and conventional imaging diagnoses. The SWE velocity values would then decrease as the flow reversal in the portal veins normalized, with the patient starting to have less ascites and returning to their baseline weight (Fig. 3 ). Patient 5 had an interesting clinical course, where the SWE velocities increased when he was first diagnosed with SOS and then the values decreased once an abdominal drain was placed to remove a large amount of ascites. The SWE values then ROC analysis demonstrated an AUC of 0.78 at day +5 and 0.85 at day +14 (Fig. 4) . A velocity increase of 0.26 m/ s over baseline at day +5 results in a sensitivity of 60% and specificity of 90% and a velocity increase of 0.085 m/s over baseline at day +5 results in a sensitivity of 80% and specificity of 67%. A velocity increase of 0.44 m/s over baseline at day +14 results in a sensitivity of 80% and specificity of 93%. Using the values of 0.085 m/s at day +5 and 0.44 m/s on day +14, four of five patients would have been diagnosed with SOS on day +5 after HSCT and the final patient would have been diagnosed at day +18. The dates of SWE SOS diagnosis were 9.2 ± 5.7 days (95% CI = 2.1 to 16.3, p = 0.0228) before the date of clinical diagnosis and 11 ± 5.2 days (95% CI = 4.5 to 17.5, p = 0.0094) before the date of conventional imaging diagnosis.
Discussion
Our study results show that changes in SWE velocities occur much earlier than traditional US Doppler measures of reversal of portal venous flow or clinical diagnosis of SOS. As early as day +5 after transplant, patients who developed SOS had significantly increased liver stiffness as measured by SWE compared to patients who did not develop SOS.
These velocity increases were even more pronounced by day +14. Our study showed that SWE identified patients who developed SOS on average 9 and 11 days earlier than our current clinical or conventional imaging criteria, respectively.
Our patient population had a similar incidence of SOS (20.0%) compared to prior report in adult literature reports [1] . Also, our findings support the established literature indicating that busulfan containing preparative regimens are associated with increased SOS risk [1] . Our data can be compared to three adult studies that have investigated SWE in the setting of HSCT. The first study is a case series of two patients who developed SOS; both patients were shown to have increased SWE velocities while they had SOS [16] . The difference between our study and this case series is that the authors measured only the SWE values at the clinical peak of the disease while we took measurements before the conditioning regimen, before the clinical peak of SOS (day +5), andnear the time of clinical peak (day +14). In the case series, the authors were also able to show that the SWE values decreased into the normal range after the patients' episodes of SOS. In a second adult study, described in a letter to the editor, researchers performed transient elastography (TE), a type of SWE, before HSCT in a cohort of 67 patients [17] . Their study showed that the pre transplant velocities were increased in patients who eventually developed hepatotoxicity from their HSCT as indicated by high bilirubin levels (>2.0 mg/dL). They did not perform any measurements after the patients initial US. Our small cohort by contrast, showed no difference in SWE velocities in the pre-conditioning phase. The discrepancy between their results and ours may be due to small sample size differences, differences in adult versus pediatric populations, the universal use of ursodiol in our study, or the fact that we were interested mainly in SOS, while they investigated all causes of hepatotoxicity. The third study is a prospective study that showed changes in TE and ARFI, a form of SWE, in adult HSCT patients. Values were elevated in adult HSCT patients who developed hepatic complications of HSCT versus those who did not. Our results are different from this study because we focused only on SOS as a complication and performed US only within the five week period following transplant. This difference likely accounted for our improved test measures for SWE in the right hepatic lobe compared to the results cited in this study.
Our study shows that SWE has the possibility of diagnosing SOS earlier compared to current imaging or clinical criteria. Early diagnosis could lead directly to improved patient outcomes. Corbacioglu et al. showed in 2004 that the average delay from diagnosis of SOS to start of defibrotide was 1.5 days in a group that had complete resolution of their SOS and 5.2 days in a group that did not have complete resolution of their SOS (p < 0.01) [18] . Just as importantly, this effect was also observed in a subgroup of patients with severe disease, where the mortality was 64% at 100 days in their cohort (1.3 versus 5.5 days; p < 0.01).
Our study shows that we can increase the diagnosis lead time by 9-11 days. The longer lead time would give clinicians many more days to decide whether to start defibrotide earlier for SOS treatment.
Our study has a few limitations. First, our study included a relatively small population from a single center. Second, the scheduled US were also performed only at day +5 and day +14, so it is hard to know if the SWE changes could be detected even earlier. Third, most cases of SOS in our patient population were mild, and there were only five cases of SOS overall. Despite these limitations, the data on SWE were clinically and statistically significant. A larger clinical trial is needed to better detect the association between SOS and increased SWE.
In conclusion, SWE velocity changes occur 9-11 days earlier than imaging or clinical findings in patients who develop SOS after HSCT. Earlier diagnosis has the potential to improve patient outcomes by earlier initiation of defibrotide.
